Complexes of il-15 and il-15ralpha and uses thereof
AssigneesNovartis AG, The United States of America, as represented by the Secretary, Department of Health and Human Serv
InventorsBarbara K. FELBER, Sergio FINKIELSZTEIN, George N. PAVLAKIS, John V. VOURNAKIS
Life of this patent
Estimating the term…
Abstract
The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-β-1-♦4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
Claims18
1-22. (canceled)
A method of recombinantly producing a human IL-15 and a human IL-15Ra complex, comprising:
- (a) culturing a cell expressing a human IL-15 encoded by a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 489 of SEQ ID NO:2;
- and a human IL15Ra encoded by:
- (i) a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 804 of SEQ ID NO:5;
- or (ii) a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 615 of SEQ ID NO:6 and
- (b) purifying the human IL-15 and human IL-15Ra complex.
A method of treating cancer in a human subject in need thereof comprising administering to the human subject a composition comprising cancer cells engineered to recombinantly co-express (i) human IL-15 or derivative thereof, and (ii) human IL-15 receptor alpha (IL-15Ra″) or a derivative thereof.
A method of making cancer cells recombinantly expressing human IL-15 and human IL-15Ra, the method comprising introducing into cancer cells a nucleic acid construct(s) encoding recombinant human IL-15 or a derivative thereof and human IL-15Ra or a derivative thereof.
Dependencies are inferred from the claim text.